Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMGTL8Z)

Drug Name

ZP-1848 Drug Info

Synonyms

Glucagon-like peptide-2 analog (inflammatory bowel disease/ Crohn's disease), Zealand

Indication

Disease Entry	ICD 11	Status	REF
Inflammatory bowel disease	DD72	Phase 1	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Glucagon-like peptide 2 receptor (GLP2R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Teduglutide	DMYOAKS	Short bowel syndrome	KB89.1	Approved	[3]
Elsiglutide	DMB7CPG	Diarrhea	ME05.1	Phase 2	[4]
SAN-134	DMWU71N	Osteoporosis	FB83.0	Phase 1	[5]
FE-203799	DMBX81R	Gastrointestinal disease	DE2Z	Investigative	[6]
AMX-256	DMGHXQE	Short bowel syndrome	KB89.1	Investigative	[6]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Glucagon-like peptide 2 receptor (GLP2R)	TT1YWO5	GLP2R_HUMAN	Modulator	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT00868660) Healthy Normal Single Ascending Dose and Crohn's Patient Multiple Ascending Dose.
2	US patent application no. 8,580,918, Peptidic glp-2 agonists.
3	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
4	Poster Abstracts. Volume 10, Issue Supplement S8, pages 126-209, December 2014.
5	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020865)
6	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 250).